263 related articles for article (PubMed ID: 21471962)
21. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M
Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969
[TBL] [Abstract][Full Text] [Related]
22. Nephrogenic systemic fibrosis developed after recovery from acute renal failure: gadolinium as a possible aetiological factor.
Lu CF; Hsiao CH; Tjiu JW
J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):339-40. PubMed ID: 18573157
[No Abstract] [Full Text] [Related]
23. Update on nephrogenic systemic fibrosis.
Thomsen HS; Marckmann P; Logager VB
Magn Reson Imaging Clin N Am; 2008 Nov; 16(4):551-60, vii. PubMed ID: 18926421
[TBL] [Abstract][Full Text] [Related]
24. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
Idée JM; Port M; Dencausse A; Lancelot E; Corot C
Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
[TBL] [Abstract][Full Text] [Related]
25. Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era.
Wang SC
J Med Imaging Radiat Oncol; 2008 Aug; 52(4):305-6. PubMed ID: 18811752
[No Abstract] [Full Text] [Related]
26. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
Weinreb JC; Abu-Alfa AK
J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
[TBL] [Abstract][Full Text] [Related]
27. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 2.
Thomsen HS
Acta Radiol; 2016 Jun; 57(6):643-8. PubMed ID: 26802070
[No Abstract] [Full Text] [Related]
28. Nephrogenic systemic fibrosis: histology and gadolinium detection.
Thakral C; Abraham JL
Radiol Clin North Am; 2009 Sep; 47(5):841-53, vi-vii. PubMed ID: 19744599
[TBL] [Abstract][Full Text] [Related]
29. Nephrogenic systemic fibrosis and contrast medium-induced nephropathy: a choice between the devil and the deep blue sea for patients with reduced renal function?
Lind Ramskov K; Thomsen HS
Acta Radiol; 2009 Nov; 50(9):965-7. PubMed ID: 19863403
[No Abstract] [Full Text] [Related]
30. [Nephrogenic systemic fibrosis and gadolinium contrast agents].
Aguilera C; Agustí A
Med Clin (Barc); 2011 May; 136(14):643-5. PubMed ID: 21397280
[No Abstract] [Full Text] [Related]
31. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid.
Nazarian RM; Mandal RV; Kagan A; Kay J; Duncan LM
J Am Acad Dermatol; 2011 Apr; 64(4):741-7. PubMed ID: 21414498
[TBL] [Abstract][Full Text] [Related]
32. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration.
Yang L; Krefting I; Gorovets A; Marzella L; Kaiser J; Boucher R; Rieves D
Radiology; 2012 Oct; 265(1):248-53. PubMed ID: 22923714
[TBL] [Abstract][Full Text] [Related]
33. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
Kitajima K; Maeda T; Watanabe S; Ueno Y; Sugimura K
Int J Urol; 2012 Sep; 19(9):806-11. PubMed ID: 22571387
[TBL] [Abstract][Full Text] [Related]
34. Gadolinium-induced nephrogenic systemic fibrosis.
Hellman RN
Semin Nephrol; 2011 May; 31(3):310-6. PubMed ID: 21784280
[TBL] [Abstract][Full Text] [Related]
35. Correction to the relative risk calculation for gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis.
Jain R; Levine M
Radiology; 2010 Apr; 255(1):307-8; author reply 308. PubMed ID: 20308469
[No Abstract] [Full Text] [Related]
36. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
Kribben A; Witzke O; Hillen U; Barkhausen J; Daul AE; Erbel R
J Am Coll Cardiol; 2009 May; 53(18):1621-8. PubMed ID: 19406336
[TBL] [Abstract][Full Text] [Related]
37. Rehabilitation in nephrogenic systemic fibrosis.
Ramaizel L; Sliwa JA
PM R; 2009 Jul; 1(7):684-6. PubMed ID: 19627963
[No Abstract] [Full Text] [Related]
38. Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD?
Martin DR
Am J Kidney Dis; 2010 Sep; 56(3):427-30. PubMed ID: 20728788
[No Abstract] [Full Text] [Related]
39. Nephrogenic systemic fibrosis and the role of gadolinium contrast media.
van der Molen AJ
J Med Imaging Radiat Oncol; 2008 Aug; 52(4):339-50. PubMed ID: 18811757
[TBL] [Abstract][Full Text] [Related]
40. Nephrogenic systemic fibrosis: clinical spectrum of disease.
Mayr M; Burkhalter F; Bongartz G
J Magn Reson Imaging; 2009 Dec; 30(6):1289-97. PubMed ID: 19937929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
